REGENXBIO Inc.

Nasdaq RGNX · Rockville, MD

Works in Dermatology · Genetic & rare · Metabolic & endocrine · Musculoskeletal · Neurology

REGENXBIO Inc. is a clinical trial sponsor based in Rockville, MD, listed as Nasdaq RGNX. It has 7 active clinical trials with 429 planned participants, across 5 therapeutic areas. Since 2021 it has completed 4 trials and stopped 5 early.

Trial track record · since 2021

7Active trials429 planned participants
4Completed2 with results posted
5Stopped early56% of finished trials

Financials · Nasdaq RGNX

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 7 active trials

StageTrialStatus

Questions about REGENXBIO Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-19.

Approve Suite is not affiliated with REGENXBIO Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.